Condition: Type 1 Diabetes · Sponsor: Assistance Publique - Hôpitaux de Paris
Type 1 diabetes (T1D) is caused by the destruction of insulin-producing cells by effector T cells (Teffs), due to a deficiency of regulatory T cells (Tregs). Ciclosporin effectively blocks the Teffs and controls diabetes, but cannot be considered as a long-term treatment. Low-dose interleukin-2 (ld IL-2) activates and expands Tregs in humans. Hence, Ld IL-2 in patients in whom the autoimmune process was blocked early by a short treatment (2 months) of cyclosporine should restore immune homeostasis and maintain some insulin production over the long term.
This description comes directly from the study's public registry record.
David Klatzmann, MD, Ph.D · 01 42 17 74 61 · david.klatzmann@sorbonne-universite.fr
Roberta Lorenzon, MD · 01 42 17 65 16 · roberta.lorenzon@sorbonne-universite.fr
Always discuss trial participation with your own doctor first.
| Lorenzon Roberta | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05153070